# FlashCell

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/flashcell

- Industry: Biotechnology
- Headquarters: Toulouse, France
- Total disclosed funding: $0.8M
- Latest round: Seed (Dec 23, 2016)
- Investors on record: 1

## About

Funded in 2016 and based in Toulouse, France, FlashCell, a spin-off of Vectalys, is a gene therapy company that focuses on developing therapeutic applications for the treatment of various diseases. As of 2018, the company is being led by its CEO, Pascale Bouillé. In May 2018, FlashCell was acquired by Flash Therapeutics. 

The firm employs its proprietary, non-integrative LentiFlashTM technology that delivers RNA-based therapeutics facilitated by genetic material transfer into the genomic DNA of target cells. The platform targets and cures disease areas such as cancer, and viral or genetic diseases by developing innovative treatments mediated by RNA delivery.

## Funding rounds

- Seed, Dec 23, 2016, $0.8M — Auriga Partners

## Investors

- Auriga Partners (https://capitalatlas.ai/funds/auriga-partners) — Seed